IMMVF (Immunovia AB) Other Current Receivables: $0.23 Mil (As of Mar. 2026)


IMMVF Immunovia AB IMMVF
43 GF Score
Price $0.02
GF Value $0.01
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Other Current Receivables?

Immunovia AB IMMVF -61.59% 43 Other Current Receivables is $0.23 Mil as of Mar. 2026. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review.

Immunovia AB's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.23 Mil.

Immunovia AB's quarterly Other Current Receivables declined from Sep. 2025 ($0.24 Mil) to Dec. 2025 ($0.14 Mil) but then increased from Dec. 2025 ($0.14 Mil) to Mar. 2026 ($0.23 Mil).

Immunovia AB's annual Other Current Receivables increased from Dec. 2023 ($0.13 Mil) to Dec. 2024 ($0.20 Mil) but then declined from Dec. 2024 ($0.20 Mil) to Dec. 2025 ($0.14 Mil).

Immunovia AB Other Current Receivables Related Terms

Immunovia AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Other Current Receivables Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.33 0.13 0.20 0.14

Immunovia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.35 0.24 0.14 0.23
IMMVF
43GF Score
Immunovia AB IMMVF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.23 Mil mean?
Immunovia AB (IMMVF) has a Other Current Receivables of $0.23 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Other Current Receivables too high?
Immunovia AB's current Other Current Receivables is $0.23 Mil. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Other Current Receivables compare to TMO and DHR?
Immunovia AB's Other Current Receivables of $0.23 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Immunovia AB and its competitors. Immunovia AB's current Other Current Receivables is $0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Other Current Receivables of $0.23 Mil. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Other Current Receivables is $0.23 Mil. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Other Current Receivables is $0.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (IMMVF) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.

Key valuation signals for IMMVF:

  • Other Current Receivables: $0.23 Mil
  • GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for IMMVF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.01
GF Value